PTEN and breast cancer: Therefore, the primary aim of our study was to investigate the association of pCR with ERBB family and PIK3CA mutations and PTEN loss (defined as PI3K pathway activation) in primary HER2-positive breast cancer treated with one or two HER2-targeting agents.